Efficacy and Safety of Two Fosfomycin Regimens as Antimicrobial Prophylaxis for Transrectal Prostate Biopsy: A Randomised Study
| Autor: | Mona Kafka, T. Tony Cai, Armin Pycha, Salvatore Palermo, E. Hanspeter, Stefan Pycha, Emanuela Trenti, Carolina D'Elia, Christine Mian, Christian Ladurner, Omar Saleh, Greta Spoladore |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Image-Guided Biopsy
Male medicine.medical_specialty Prostate biopsy Urology 030232 urology & nephrology Prostatitis Fosfomycin Group B 03 medical and health sciences Prostate cancer Postoperative Complications 0302 clinical medicine Clinical Protocols Prostate medicine Humans Prospective Studies Aged medicine.diagnostic_test business.industry Gold standard Rectum Prostatic Neoplasms Bacterial Infections Antibiotic Prophylaxis Middle Aged medicine.disease Comorbidity Anti-Bacterial Agents Treatment Outcome medicine.anatomical_structure 030220 oncology & carcinogenesis business medicine.drug |
| Zdroj: | Urologia Internationalis. 103:433-438 |
| ISSN: | 1423-0399 0042-1138 |
| Popis: | Purpose: Prostate biopsy is the gold standard for prostate cancer diagnosis; unfortunately, this procedure is not free from complications. Recent studies have shown an increase in antibiotic resistance. The aim of our prospective randomized study was to evaluate the efficacy and safety of a prostate biopsy prophylaxis protocol using 2 vs. 3 fosfomycin doses. Methods: Two hundred and ninety-seven patients undergoing transrectal systematic ultrasound (US)-guided (n = 277) or transrectal fusion prostate biopsy (n = 20) were prospectively evaluated and randomized by date of birth, to receive 2 (even years, group A) versus 3 doses of fosfomycin (odd years, group B), and prospectively evaluated. Results:Two hundred and ninety-seven patients were randomized to group A (n = 162) or group B (n = 135). The 2 groups were comparable with respect to age, comorbidity, PSA value, prostate volume, operative time and urine culture results. Out of 297 patients, 44 (14.8%) developed complications after the procedure; 2.7% (8/297) of patients developed fever >38° requiring hospitalization (6 [3.7%] in group A and 2 [1.5%] in group B, p = 0.29). Patients who underwent fusion biopsy were more frequently readmitted in comparison with patients undergoing US-guided prostate biopsy (p = 0.000). Conclusion: The low fever and prostatitis rate suggest that fosfomycin prophylaxis is safe and efficient. There is no significant difference in clinical outcome between the 2 dosage regimens. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|